Last reviewed · How we verify
NCT07043907
PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC
Phase 2 trial testing PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy in Stage IIIA Non-small Cell Lung Cancer in 115 participants. Not yet recruiting.
8 July 2028
Quick facts
| Lead sponsor | Shenzhen Celconta Life Science Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 115 |
| Start date | 8 July 2025 |
| Primary completion | 8 July 2028 |
| Estimated completion | 18 June 2029 |
Drugs / interventions tested
- PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy — full drug profile →
Conditions studied
- Stage IIIA Non-small Cell Lung Cancer — all drugs for Stage IIIA Non-small Cell Lung Cancer →
Sponsor
Shenzhen Celconta Life Science Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Stage IIIA Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07043907
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stage IIIA Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT05894889 — Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC · Phase 2 · active not recruiting
- NCT05167487 — Pathological Response After Neoadjuvant Treatment on NSCLC · recruiting
- NCT04776447 — Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) · Phase 2 · active not recruiting
- NCT01345851 — Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemother · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07043907 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Celconta Life Science Co., Ltd.
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07043907.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing